European Roll Out For Samsung Bioepis's Etanercept Biosimilar
This article was originally published in PharmAsia News
After gaining two regulatory approvals for its biosimilars at home last year, South Korea's Samsung Bioepis has now received its first overseas clearance for an etanercept biosimilar, in Europe. Benepali, which will be Europe's first biosimilar version of the fusion protein, is set to enter 31 European markets.
Register for our free email digests: